Clinical Trials Logo
  1. Home
  2. Chemotherapy
  3. NCT00211601

Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041) — C-PHONE  

Chemotherapy Induced Nausea and Vomiting Clinical Trial

Official title:
Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis

Clinical Trial Summary

The purpose of this study is to assess whether timely feedback to providers on patient experiences with delayed chemotherapy induced nausea and vomiting (CINV) lead to differences in patient outcomes for subsequent cycles.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00211601
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase N/A
Start date August 2004
Completion date December 2005
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06065722 - Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy Phase 2
Completed NCT01362530 - A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208) Phase 3
Recruiting NCT02205164 - Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients Phase 2
Completed NCT01596400 - Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years Phase 1
Not yet recruiting NCT04873284 - Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients N/A
Completed NCT00642512 - Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting Phase 3
Recruiting NCT02097823 - Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy Phase 2
Completed NCT01402024 - Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy Phase 3
Completed NCT05792228 - A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting N/A
Withdrawn NCT01596426 - Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years Phase 1
Withdrawn NCT01596413 - Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years Phase 1